Literature DB >> 24191923

[Juvenile idiopathic arthritis: from biomarker to treatment].

Charlotte M Nusman1, J Merlijn van den Berg, Dieneke Schonenberg-Meinema, Mario Maas, Rebecca ten Cate, Taco W Kuijpers.   

Abstract

Juvenile idiopathic arthritis (JIA) is the most common cause of chronic joint inflammation in childhood. The aetiology is unknown and the pathogenesis is multifactorial. JIA manifests itself in many various ways. It is a diagnosis of exclusion: other disorders need to be ruled out for a diagnosis to be made. MRI examination is playing an increasingly important role in making a correct early diagnosis and in assessing response to therapy. After 6 months JIA patients are classified, based on clinical characteristics and laboratory results, into one of the JIA categories according to the criteria of the International League of Associations for Rheumatology. Recent developments in therapy, such as starting biological treatment at an early stage, have led to an improvement in the prognosis of JIA and to structural joint damage occurring less often.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24191923

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  1 in total

1.  Study of the association between CD28/CTLA-4 expression and disease activity in juvenile idiopathic arthritis.

Authors:  Lei Zhang; Hui Liang; Hui Guan; Hualin Liu
Journal:  Exp Ther Med       Date:  2015-02-17       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.